Contents
Administrative Procedure Act in Question
Another major issue involves the Administrative Procedure Act (APA), which governs how federal agencies implement new regulations. The APA requires that most new rules go through a formal notice-and-comment period to ensure transparency and public input.
Because Trump’s executive order pressures the Department of Health and Human Services (HHS) to act within 180 days, some legal scholars argue this timeline could be seen as bypassing the APA. If the rule is implemented without the proper procedural steps, it may be struck down in court as “arbitrary and capricious.”
Drug Importation and FDA Oversight
The executive order also encourages the importation of lower-priced prescription drugs from foreign markets. However, the Food and Drug Administration (FDA) has strict standards designed to protect consumers from counterfeit or unsafe drugs.
Allowing foreign drugs into the U.S. raises concerns about safety, regulatory consistency, and quality control. While several states have pushed for drug importation in recent years, the FDA has traditionally resisted widespread implementation due to health risks and legal uncertainty.
Potential Trade and IP Conflicts
Tying domestic drug prices to foreign markets could also trigger international trade conflicts and intellectual property disputes. Pharmaceutical companies argue that forced price alignment undermines research investment and violates trade agreements protecting patents and pricing autonomy.
Critics claim the MFN model may violate obligations under World Trade Organization rules or bilateral trade deals. If enacted, this executive order could open the door for retaliatory measures or formal disputes from trade partners.
What Happens Next
The MFN pricing rule is expected to face immediate legal challenges from the pharmaceutical industry, patient advocacy groups, and possibly members of Congress. These challenges may delay or derail the policy altogether.
As the policy moves toward implementation, courts will likely determine whether the Trump administration followed proper procedures and stayed within legal bounds. In the meantime, the debate over how best to reduce drug prices in the U.S. remains at the forefront of healthcare policy and legal scrutiny.
